POMB/ACE chemotherapy for mediastinal germ cell tumours

Bower, Mark; Brock, Cathryn; Holden, L.; Nelstrop, Ann E.; Makey, A. R.; Rustin, G. J. S.; Newlands, E. S.

doi:10.1016/s0959-8049(96)00403-0

Cited by 13 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If serum markers have normalized after chemotherapy, resection of all residual abnormalities on imaging studies of the mediastinum is recommended 2,3 . But in two studies surgical resection with elevated serum markers are recommended to prevent chemoresistance 7,8 . In our case the persistence of a mass after chemotherapy without elevation of serum markers and without surgical resection available made us maintain a strict observation attitude.…”

Section: Discussionmentioning

confidence: 99%

Giant residual non-seminonatous mediastinal mass

Ocaña¹,

Ceballos

Marcos

et al. 2004

Oncología (Barc.)

View full text Add to dashboard Cite

Summary• Purpose: To point out the difficult therapeutic management of mediastinal germ-cell tumors and the residual masses.• Material and methods: We present a patient with a mediastinal non-seminomatous germcell tumor and the therapeutic management of the residual mass.• Results and conclusion: Surgical resection is the therapeutic attitude with regard to a resi- • Material y Métodos: se presenta el caso de un paciente con un tumor germinal no seminomatoso mediastínico y el manejo terapéutico de la masa residual.• Conclusiones: ante una masa residual no seminomatosa mediastínica con marcadores negativos la actitud terapéutica es la quirúrgica.Palabras clave: Masa mediastínica. Tumor germinal. Masa residual.

show abstract

Section: Discussionmentioning

confidence: 99%

Giant residual non-seminonatous mediastinal mass

Ocaña¹,

Ceballos

Marcos

et al. 2004

Oncología (Barc.)

View full text Add to dashboard Cite

show abstract

“…Following the success of combination chemotherapy in seminoma [101]and teratoma [87, 102, 103, 104], platinum-based regimes are curing the majority of women with metastatic or incompletely resected ovarian GCT (table 4). In the 1970s the most commonly used regimen was VAC, both as adjuvant in stage I and also as treatment for advanced disease [105].…”

Section: Combination Chemotherapy For Advanced Ovarian Gctmentioning

confidence: 99%

Management of Non-Epithelial Ovarian Tumours

Bridgewater

Rustin²

1999

Oncology

View full text Add to dashboard Cite

Ovarian tumours of non-epithelial origin are less common than those of epithelial origin but must be distinguished from these as their natural history and management differ. As these tumours are rare, histological review by an expert in the field is essential. There have been no randomised trials to outline the management of these tumours and therefore this paper represents a review of descriptive data. Non-epithelial ovarian tumours, which represent approximately 50% of all ovarian tumours and approximately 25% of malignant ovarian tumours, are outlined. Lymphomas and metastatic tumours should be treated the same as when found in other sites and will not be discussed further.

show abstract

“…56,63 Despite the suggestion that chemotherapy is a superior modality (more so in bulky inoperable MS), the toxicity can be significant. 54,55 The selection of the initial modality is made more difficult because of the fact that radiotherapy is far less toxic, and because salvage rates with chemotherapy after radiotherapy failure are high. 53 As a general management guideline for MS, we would recommend only postoperative mediastinal RT for smaller obviously resectable tumours, with neo-adjuvant platinumbased chemotherapy reserved for bulky lesions.…”

Section: Seminomamentioning

confidence: 99%

“…Further cycles of chemotherapy were recommended if residual disease was present at surgery. 55 An attempt at major debulking surgery after diagnosis, in order to achieve a complete response, is not recommended due to potential postoperative delay in the commencement of chemotherapy. 55…”

Section: Non-seminomatous Germ Cell Tumourmentioning

confidence: 99%

“…In addition, high-dose chemotherapy with haemopoietic stem cell support has been shown to be inactive as salvage treatment. 55,[80][81][82][83] Although having a 65% response rate for such therapy, Broun et al reported only a 15% long-term survival. 83 Interestingly, however, a recent German study of 74 patients with recurrent or refractory GCT were treated with two cycles of conventional dose salvage chemotherapy followed by one cycle of high-dose chemotherapy comprising carboplatin (1500-2000 mg/m 2 ), etoposide (1200-2400 mg/m 2 ), ifosfamide (0-10 mg/m 2 ), with autologous stem cell rescue thereafter.…”

Section: Refractory or Relapsing Extragonadal Germ Cell Tumoursmentioning

confidence: 99%

See 1 more Smart Citation

Primary malignant mediastinal germ cell tumours: A literature review and a study of 18 cases

Kiffer

Sandeman

1999

Australasian Radiology

View full text Add to dashboard Cite

From 1957 to 1992, 18 cases of primary mediastinal germ cell tumours were referred to the Peter MacCallum Cancer Institute (PMCI). Six were seminomas, six were mixed germ cell tumours, two were embryonal cell carcinomas, three were teratocarcinomas and one was labelled an 'anaplastic germ cell tumour'. Two of the 18 patients were female. For seminomas, surgical (and in one case chemotherapeutic) debulking, followed by radiotherapy produced the best results. Mediastinal doses ranged from 30 to 40 Gy. Local control was achieved in those patients receiving mediastinal radiotherapy. Four patients currently survive disease-free. The non-seminomatous germ cell tumours showed a significantly poorer survival, and only two of 12 patients remain alive in remission at 110 and 130 months after diagnosis. Survival has been updated as of November 1997. Attention is focused on the anterior position of the primary germ cell tumours in the mediastinum. A review of the literature up to and including 1997 is presented.

show abstract

POMB/ACE chemotherapy for mediastinal germ cell tumours

Cited by 13 publications

References 26 publications

Giant residual non-seminonatous mediastinal mass

Giant residual non-seminonatous mediastinal mass

Management of Non-Epithelial Ovarian Tumours

Primary malignant mediastinal germ cell tumours: A literature review and a study of 18 cases

Contact Info

Product

Resources

About